Technical Session V Policy and Institutional Frameworks for Hi- tech Innovation Systems Modern biotechnology
Technical Session VPolicy and Institutional Frameworks for Hi-tech Innovation Systems
Modern biotechnology
Year 2030 Bioeconomy
OECD: The bioeconomy in 2030 is likely to involve three elements: 1. advanced knowledge of genes and complex cell processes2. renewable biomass3. integration of biotechnology applications across sectors.
OECD = the Organization for Economic Co-operation and Development
Bioeconomy: Born from necessity : Need innovation to meet the challenges
Energy crisis
Climate change &Resource crisis
Emerging diseases Well being & Aging people
pollution
Biotechnology: the fourth wave to solve the global problems
Green products
Green process
Plants: high production + resistant traitsBioremediation
Diagnostic deviceMedical systemVaccine
NutraceuticalFunctional food
Specific Characteristics of Biotech Business
• Knowledge based industry
• Diverse benefit
• High investment and long-term return (~3-10 years)
• SMEs (Size < 100 employees)
• High control & regulation
• Market oriented
http://www.slideshare.net/danielsatinsky/boston-innovation-ecosystem-st-petersburg
Heart of innovation ecosystem is the regular and constant interaction bringing great science with entrepreneurs
To help reduce some risks, government needs to provide suitable supports: Innovation ecosystem
http://www.biowin.org/biowin/en/5408-home.html
To create innovation ecosystem, Wallonia region identify 6 competitive clustersStrategy of the BioWin cluster (health cluster)
BioWin is a not-for-profit organization. This unit is governed by a governing board, assisted by a permanent operational team.
BioWin gathers more than500 members:• 130 companies (125 SMEs and 5 Global leaders: Baxter, GSK, IBA, UCB, and Eurogentec-Kaneka • 400 research centers, 5 universities
2x2 model for innovation
Open Innovation• Key elements: networking, collaboration with partners, competitors, universities, and users • proactive intellectual property management• R&D to obtain competitive advantage
“Partners with others to create the most and the best ideas in the industry”
“ Make profit from the other’s use of our IP, and also buy others’ IP when it advances our business model”
Specify future niche direction from own strength and alsoNation’s master plan
USA - medical innovation focusing human health- food & agriculture- biobased industry using industrial enzyme
Japan- medical technology- in vitro diagnostics- drug discovery- medical device, functional food
Taiwan - Hub of clinical trial in Asia- focus on traditional Chinese herbal medicines
Process to identify niche direction1. Select innovation/capability focus2. Uncover customer needs3. Priority customer needs4. Develop strategy
Provide suitable environment … vision with commitment
USA- provide tax incentives for SMEs - support source of money (venture capital funding)
Malaysia- Create Bill of Guarantees for biotech companies to ensure IP protection and freedom to import capital and labor- Create BiotechCorp as a convenient one-stop shop for biotech companies providing funding and assistance with IP, immigration, regulation, and employment matters- Launched the Biotechnology Commercialization Fund
Singapore- Commercialization framework via Exploit Technologies (business arm of A*STAR) bridging R&D to industry- government incentives ex. Match $ per $- world-class R&D infrastructure
Suitable environment• budget• infrastructure• host • etc.
Set up systems to expedite technology transfer and commercialization
Soft services to serve researchers and startups• IP protection• incubation: coaching & mentoring• commercialize process & marketing
https://www.bio.org/sites/default/files/GPP-FINAL-2-1-2013.pdf
Provide a transparent and predictable regulatory approval process
Singapore- Integration among govt. and private agencies: : Biomedical Research council: Singapore Economic Development Board (EDB): Biomedical Science Group: Ministry of Health (MOH),and Bio*One Capital: A*STAR Joint Council to support interdisciplinary researchTaiwan
- Multiministerial efforts supervised by Science and Technology Advisory Group of the Executive Yuan (Cabinet): National Science Council + the Ministry of Economic Affairs
Maintain transparent, non-discriminatory, competitive, and commercially viable market for biotech productsUSA launches BioPreferred program to certify
biobased products (government procurement)
• managed by the US Department of Agriculture (USDA) • to increase the purchase and use of bio-based products • 2 major parts of the program: - mandatory purchasing requirements for federal agencies and their contractors - voluntary labeling initiative for bio-based products
Thai Government Policy to support STI
Increase R&D investment to 1% of GDPRatio of public and private = 30:70
Support Maga projectsUse Thai innovation for government procurement
Create innovation society - STEM education- talent mobility
Improve law & regulation to push R&D for commercialization
Develop infrastructure for science, technology, and innovation
http://unctad.org/meetings/en/Presentation/ecn162015p15_Durongkaveroj_en.pdf
http://unctad.org/meetings/en/Presentation/ecn162015p15_Durongkaveroj_en.pdf
Area: 80 AcresSpace: 140,000 m2
Types of space: Incubator units, wet/dry labs, long-term leased land
At present: 60 companies, 20 incubatees
Thailand Science ParkThailand Science Park
Infrastructure for Knowledge Business
Convention CenterMulti-tenant Incubator
BuildingGreenhouse
Pilot PlantNational Centers
Thailand Science Park - Phase 2
• Four integrated towers• Gross area of around 127,000 sq.m., Net area of 72,000 sq.m.• 40,000 sq.m. allocated for private companies• Clean room, sensitive lab, heavy equipment areas available
NSTDA: Linkage between R&D and Business
Infrastructure & Facility
NSTDA’s soft services
http://unctad.org/meetings/en/Presentation/ecn162015p15_Durongkaveroj_en.pdf
AYUBOVON
KHOB KHUN KHA